Email this article HALLUCINOGENS: A SPECIAL CLASS OF SUBSTANCES?
- Authors: Sivolap Y.P1
-
Affiliations:
- First Moscow State University
- Issue: Vol XLIX, No 2 (2017)
- Pages: 75-77
- Section: Articles
- URL: https://journals.rcsi.science/1027-4898/article/view/14076
- DOI: https://doi.org/10.17816/nb14076
- ID: 14076
Cite item
Full Text
Abstract
Hallucinogens are a heterogeneous class of substances that include two main groups: classical hallucinogens or psychedelics produce serotonergic effects, and dissociative hallucinogens that are glutamate NMDA receptors antagonists. Unlike alcohol and many other drugs, most hallucinogens do not have a pronounced adverse effect on health and, moreover, have some beneficial properties. Hallucinogens are not very popular among drug users, they are rarely abused, do not cause addiction, and, on the contrary, often exhibit anti-addictive properties, which makes it possible to question the legitimacy of assigning these substances to illicit drugs.
Full Text
##article.viewOnOriginalSite##About the authors
Yuri P Sivolap
First Moscow State University
Email: yura-sivolap@yandex.ru
department of psychiatry and narcology 119991, Trubetskaya Str., 8 (2), Moscow
References
- Belgers M., Leenaars M., Homberg J.R. et al. Ibogaine and addiction in the animal model, a systematic review and meta-analysis // Transl Psychiatry. 2016. Vol. 6 (5). P. e826.
- Bogenschutz M.P., Johnson M.W. Classic hallucinogens in the treatment of addictions // Prog Neuropsychopharmacol Biol Psychiatry. 2016. Vol. 64. P. 250-258.
- Gunduz-Bruce H., Kenney J., Changlani S. et al. A translational approach for NMDA receptor profiling as a vulnerability biomarker for depression and schizophrenia // Exp Physiol. 2017. [Epub ahead of print].
- Murrough J.W., Abdallah C.G., Mathew S.J. Targeting glutamate signalling in depression: progress and prospects // Nat Rev Drug Discov. 2017. [Epub ahead of print].
- Ruiz P., Strain E.C. The Substance Use: Handbook. / Second Edition. Philadelphia: Lippincott, Williams & Wilkins, 2014. 558 p.
- Ryan W.C., Marta C.J., Koek R.J. Ketamine, Depression and Current Research: A Review of the Literature. In: The Ketamine Papers: Science, Therapy, and Transformation. Santa Cruz: MAPS, 2016. P. 199-273.
- Zdrojewicz Z., Kuszczak B., Olszak N. Ibogaine - structure, influence on human body, clinical relevance // Pol Merkur Lekarski. 2016. Vol. 41 (241). P. 50-55.
